


Respiratory syncytial virus infections in hematopoietic cell transplant (HCT) recipients and hematological malignancy (HM) patients



- **Incidence of RSV infections** HCT recipients: 5%-49%; HM patients: ~ 30%
- **Risk factors** Progression from URTI to LTRI → higher mortality rate
- **Long-term complication** Reduction in pulmonary function
- **Current treatments** Ribavirin and immuno-modulators (e.g. intravenous immunoglobulins or RSV monoclonal antibodies (palivizumab))